Eisai Co., Ltd
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; BELVIQ for the treatment for chronic weight management; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which includes third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a collaboration agreement with Personal Genome Diagnostics Inc. to develop liquid biopsy biomarker discovery solution. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan. Show More...
-
Website http://www.eisai.co.jp
-
Sector Healthcare
-
Industry Drug Manufacturers-Specialty & Generic
-
Last Quote 24.41 EUR
-
Last Updated 29-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-03 2011-03 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 TTM Earnings Per Share JPY 141.56 236.51 205.31 169.31 134.01 151.37 191.76 137.41 180.97 221.12 337.21 Dividends JPY 150.0 150.0 150.0 150.0 150.0 150.0 150.0 150.0 150.0 160.0 Payout Ratio % * 63.4 86.8 98.7 97.8 102.3 95.7 78.0 147.9 67.5 47.4 Shares Mil 285.0 285.0 285.0 285.0 286.0 286.0 286.0 286.0 286.0 287.0 287.0 Book Value Per Share * EUR 12.1 11.9 12.41 12.51 15.82 16.4 17.36 15.68 16.85 18.18 Free Cash Flow Per Share * EUR 2.99 1.68 1.93 1.39 1.32 1.59 1.83 1.12 4.25 Return on Assets % 3.59 6.27 5.71 4.84 3.4 4.33 5.42 3.93 4.99 5.98 9.31 Financial Leverage (Average) 2.64 2.58 2.4 2.1 1.86 1.76 1.7 1.76 1.77 1.71 1.63 Return on Equity % 9.54 16.4 14.22 10.87 6.74 7.82 9.37 6.8 8.8 10.38 15.54 Return on Invested Capital % 5.35 8.89 8.05 6.73 4.72 5.65 7.11 4.97 6.66 7.95 12.57 Interest Coverage 10.7 14.83 14.73 11.68 11.5 6.29 15.48 18.78 26.9 58.42 94.55 Current Ratio 2.18 2.26 2.53 2.46 2.59 2.27 2.89 2.16 2.22 1.9 1.81 Quick Ratio 1.64 1.67 1.85 1.73 1.8 1.8 2.22 1.72 1.82 1.52 1.49 Debt/Equity 0.93 0.84 0.72 0.51 0.39 0.34 0.35 0.28 0.26 0.14 0.09